Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence

ABSTRACT Introduction Extensive small cell lung cancer (ES‐SCLC) are currently managed using first‐line chemotherapy options, including atezolizumab (Atezo) plus etoposide and carboplatin (CE) or durvalumab (Durva) plus etoposide with either cisplatin (PE) or carboplatin (CE). However, a definitive...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Yuta Yamanaka, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi, Yume Sanada, Kiyori Yoshida, Tatsuki Ikoma, Yuki Takeyasu, Utae Katsushima, Hiroshige Yoshioka, Takayasu Kurata
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Wiley 2024-12-01
Reeks:	Cancer Medicine
Onderwerpen:	atezolizumab durvalumab extensive‐stage small cell lung cancer first‐line treatment immune checkpoint blockade real‐world evidence
Online toegang:	https://doi.org/10.1002/cam4.70480
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!